Founder and Medical Director Montreal Glaucoma Institute and Cliniques d’ophtalmologie Bellevue
Hexiris
NHL Implant
Director Recently Retired CFO & Interim President, Devonshire Investments (Fidelity)
Director Over 25 years of experience in the biopharmaceutical industry and co-founder of Novellus, Inc
Co-founder, COO & Director
CO-FOUNDER, CO-CHIEF EXECUTIVE OFFICER AND CHIEF SCIENTIFIC OFFICER
Co-Founder, Chairman and Co-Chief Executive Officer
An experienced ophthalmologist specializes in both LASIK eye surgery and intraocular lens surgery
An ophthalmologist and glaucoma specialist, serving as Founding Medical Director of the Montreal Glaucoma Institute and Cliniques d'ophtalmologie Bellevue
Founder and Medical Director Montreal Glaucoma Institute and Cliniques d’ophtalmologie Bellevue
Director of Engineering
V.P. Operations
Chief Financing Officer
MIGS procedures use microscopic-sized equipment and tiny incisions. While they reduce the incidence of complications, some degree of effectiveness is also traded for the increased safety. Nevertheless, current MIGS devices serve an unfilled niche given the alternative traditional treatments:
Since bleb-forming MIGS involves placing a permanent implant into the eye, it circumvents the major issue plaguing glaucoma medication, which is patient non-compliance, and provides a safe, effective therapy for preventing permanent vision loss in refractory glaucoma patients.
Les chirurgie micro-invasives du glaucome (CMIG) sont réalisées à l’aide d’équipements de taille microscopique. Les dispositifs MIGS actuels offrent une solution de rechange aux traitements traditionnels :
Puisque les CMIG consistent à installer un implant permanent dans l’œil, elles permettent de remédier au principal problème lié à la prise de médicaments contre le glaucome, soit le manque de conformité chez les patients. Les CMIG constituent une thérapie sécuritaire et efficace pour prévenir la perte de vision permanente chez les patients atteints de glaucome réfractaire.